| Colleen Felton, | |
|
1 Arch Pl, Greenfield, MA 01301-2457 | |
| (413) 773-1314 | |
| Not Available |
| Full Name | Colleen Felton |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 1 Arch Pl, Greenfield, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104227230 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Entity Name | Clinical & Support Options, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831265115 PECOS PAC ID: 6608835350 Enrollment ID: O20041007000491 |
News Archive
Maxygen, Inc. (Nasdaq:MAXY) today announced the consummation of the transactions contemplated by the previously announced joint venture agreement between Maxygen and Astellas Pharma Inc. Under the joint venture transaction, which closed on September 18, 2009, the parties established a newly-formed joint venture, Perseid Therapeutics LLC, to focus on the discovery, research and development of multiple protein pharmaceutical programs.
Much of modern Western medicine is based upon the treatment of acute, immediate harm, from physical injury to infections, from broken bones and the common cold to heart and asthma attacks.
Despite evidence to the contrary, parents who talk to their children about sexual abuse incorrectly identify strangers as the most likely source of abuse, according to a team of researchers led by Esther Deblinger, PhD, co-director of the CARES (Child Abuse Research Education and Services) Institute at the University of Medicine and Dentistry of New Jersey(UMDNJ)-School of Osteopathic Medicine.
As part of their long-term investigation of regulatory factors in the bacterial cell cycle, molecular biologists at the University of Massachusetts Amherst now report finding a surprising new role for one factor, CpdR, an adaptor that helps to regulate selective protein destruction, the main control mechanism of cell cycle progression in bacteria, at specific times.
Over the last few decades, researchers have developed artificial enzymes for many applications. Recently, they deployed nanomaterial-based enzyme mimetics or nanozymes in diagnosis and therapeutics. Nanozymes find applications in various biomedical applications, including antiviral agents and cancer therapy.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Colleen Felton, 1 Arch Pl, Greenfield, MA 01301-2457 Ph: (413) 773-1314 | Colleen Felton, 1 Arch Pl, Greenfield, MA 01301-2457 Ph: (413) 773-1314 |
News Archive
Maxygen, Inc. (Nasdaq:MAXY) today announced the consummation of the transactions contemplated by the previously announced joint venture agreement between Maxygen and Astellas Pharma Inc. Under the joint venture transaction, which closed on September 18, 2009, the parties established a newly-formed joint venture, Perseid Therapeutics LLC, to focus on the discovery, research and development of multiple protein pharmaceutical programs.
Much of modern Western medicine is based upon the treatment of acute, immediate harm, from physical injury to infections, from broken bones and the common cold to heart and asthma attacks.
Despite evidence to the contrary, parents who talk to their children about sexual abuse incorrectly identify strangers as the most likely source of abuse, according to a team of researchers led by Esther Deblinger, PhD, co-director of the CARES (Child Abuse Research Education and Services) Institute at the University of Medicine and Dentistry of New Jersey(UMDNJ)-School of Osteopathic Medicine.
As part of their long-term investigation of regulatory factors in the bacterial cell cycle, molecular biologists at the University of Massachusetts Amherst now report finding a surprising new role for one factor, CpdR, an adaptor that helps to regulate selective protein destruction, the main control mechanism of cell cycle progression in bacteria, at specific times.
Over the last few decades, researchers have developed artificial enzymes for many applications. Recently, they deployed nanomaterial-based enzyme mimetics or nanozymes in diagnosis and therapeutics. Nanozymes find applications in various biomedical applications, including antiviral agents and cancer therapy.
› Verified 6 days ago
Jennifer Jakowski, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 48 Sanderson St, Greenfield, MA 01301 Phone: 413-773-4449 | |
Rebecca King, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 55 Federal St, Greenfield, MA 01301 Phone: 413-772-2935 Fax: 413-772-3724 | |
Lindsay P.b. Boudreau, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 140 High St, Greenfield, MA 01301 Phone: 413-772-0249 | |
Mr. Gordon David Gross, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 55 Federal St, Greenfield, MA 01301 Phone: 413-772-2935 | |
Mr. Louis Jackson Grande, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 140 High St, Greenfield, MA 01301 Phone: 413-774-5411 | |
Kasey Erickson, LICSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 22 Abbott St, Greenfield, MA 01301 Phone: 201-220-5600 | |
Christina M Kerr, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 215 Shelburne Rd, Greenfield, MA 01301 Phone: 413-774-1000 Fax: 413-774-1197 |